AU2002224037A1 - Pd-1-lacking mouse and use thereof - Google Patents

Pd-1-lacking mouse and use thereof

Info

Publication number
AU2002224037A1
AU2002224037A1 AU2002224037A AU2403702A AU2002224037A1 AU 2002224037 A1 AU2002224037 A1 AU 2002224037A1 AU 2002224037 A AU2002224037 A AU 2002224037A AU 2403702 A AU2403702 A AU 2403702A AU 2002224037 A1 AU2002224037 A1 AU 2002224037A1
Authority
AU
Australia
Prior art keywords
mice
specifically
autoimmune disease
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224037A
Inventor
Tasuku Honjo
Hiroyuki Nishimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of AU2002224037A1 publication Critical patent/AU2002224037A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Abstract

It relates to BALB/c mice that defect programmed cell death-1 receptor (PD-1), a screening method of autoimmune disease medicine by use of these mice, IgG self-reactivity antibody that the mice produce specifically, protein specifically reacted to the antibody and produced in heart, and an diagnostic method in dilated cardiomyopathy by use of the protein. Because PD-1 deficient BALB/c mice spontaneously develop autoimmune disease, specifically dilated cardiomyopathy, they are useful to screening for medicines against these diseases.
AU2002224037A 2000-11-15 2001-11-14 Pd-1-lacking mouse and use thereof Abandoned AU2002224037A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000347392 2000-11-15
JP2000-347392 2000-11-15
PCT/JP2001/009951 WO2002039813A1 (en) 2000-11-15 2001-11-14 Pd-1-lacking mouse and use thereof

Publications (1)

Publication Number Publication Date
AU2002224037A1 true AU2002224037A1 (en) 2002-05-27

Family

ID=18821130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224037A Abandoned AU2002224037A1 (en) 2000-11-15 2001-11-14 Pd-1-lacking mouse and use thereof

Country Status (8)

Country Link
US (1) US7414171B2 (en)
EP (1) EP1334659B1 (en)
JP (2) JP3871326B2 (en)
KR (1) KR20030066657A (en)
AT (1) ATE540579T1 (en)
AU (1) AU2002224037A1 (en)
CA (1) CA2429042C (en)
WO (1) WO2002039813A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
WO2004091476A2 (en) 2003-04-16 2004-10-28 Ono Pharmaceutical Co Method of screening remedy for heart disease and medicinal composition for treating heart disease
CN101050473B (en) * 2007-02-09 2010-08-18 北京大学 Kit for sieving medication of anti cell proliferation or anti tumor, sieving method and usage
SG10201708690SA (en) * 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
DK2992017T3 (en) 2013-05-02 2021-01-25 Anaptysbio Inc ANTIBODIES AGAINST PROGRAMMED DEATH-1 (PD-1)
HUE049281T2 (en) 2013-09-13 2020-09-28 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
US10390522B2 (en) 2014-06-19 2019-08-27 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
WO2016000619A1 (en) 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
RU2711141C2 (en) 2014-07-22 2020-01-15 СиБи ТЕРЕПЬЮТИКС, ИНК. Anti-pd-1 antibodies
NZ728749A (en) 2014-08-05 2023-06-30 Cb Therapeutics Inc Anti-pd-l1 antibodies
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
EP3481393B1 (en) 2016-07-05 2021-04-14 Beigene, Ltd. Combination of a pd-1 antagonist and a raf inhibitor for treating cancer
FI3500299T3 (en) 2016-08-19 2024-02-14 Beigene Switzerland Gmbh Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
BR112019008859A2 (en) 2016-11-01 2019-07-09 Anaptysbio Inc antibodies directed against programmed death 1 (pd-1)
SG11201906192SA (en) 2017-01-09 2019-08-27 Tesaro Inc Methods of treating cancer with anti-pd-1 antibodies
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
TWI804572B (en) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 Bispecific antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143491C (en) * 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it

Also Published As

Publication number Publication date
JP2007023047A (en) 2007-02-01
JP3871326B2 (en) 2007-01-24
CA2429042C (en) 2012-09-25
EP1334659A4 (en) 2007-07-11
KR20030066657A (en) 2003-08-09
CA2429042A1 (en) 2002-05-23
JP4018122B2 (en) 2007-12-05
WO2002039813A1 (en) 2002-05-23
US7414171B2 (en) 2008-08-19
ATE540579T1 (en) 2012-01-15
JPWO2002039813A1 (en) 2004-03-18
EP1334659B1 (en) 2012-01-11
US20040034881A1 (en) 2004-02-19
EP1334659A1 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
AU2002224037A1 (en) Pd-1-lacking mouse and use thereof
Nezlin The immunoglobulins: structure and function
WO2004056847A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
TR200202735T1 (en) Human monoclonal antibody against AILIM, a co-stimulated signal transduction molecule, and its pharmaceutical use
IL147638A0 (en) Human monoclonal antibodies to prostate specific membrane antigen
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2002100348A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
PL392964A1 (en) Hyperimmune serum reactive antigen, the use of this antigen for the production of a pharmaceutical formulation, fragment of the hiperimmune antigen, antigen auxiliary epitopes, a vaccine containing the hyperimmune serum reactive antigen, formulation containing antibodies, process for the preparation of this formulation, the use of the formulation for the treatment of staphylococcal infections, and screening method
WO2001085798A3 (en) Human monoclonal antibodies to dendritic cells
CN106459213A (en) Modified J-chain
CA2497287A1 (en) Method of humanizing immune system molecules
IL93118A0 (en) Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
PT1100922E (en) Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
CN106164092A (en) Performance difference combines the V of featurelantigen-binding proteins
FR2794461B1 (en) PROCESS FOR THE PREPARATION OF NEW HUMAN IG FRACTIONS HAVING IMMUNOMODULATORY ACTIVITY
NO975714D0 (en) Process for the preparation of monoclonal antibody, monoclonal antibody and pharmaceutical composition and diagnostic reagent containing the same
DE3788296D1 (en) Monoclonal antibodies to human interleukin-2 receptor.
JPH10509948A (en) Human antibodies to T cell receptor peptides and methods for their preparation
CN1226306C (en) Antibodies to placental protein 13
Butler Antigen receptors, their immunomodulation and the immunoglobulin genes of cattle and swine
WO2002055089A2 (en) Immunoassay technique using multispecific molecules
EP0376851A2 (en) Molecular recognition units
JEFFERIS Structure-function relationships of IgG
CN112206327A (en) Preparation of antibody coupling drug and high-throughput screening method thereof
RU2240823C2 (en) Method for obtaining fluorescent antispecies conjugate against human or animal immunoglobulins g for reaction of indirect immunofluorescence